01
Funding
Isomorphic Labs raises $5 billion to move AI-designed drugs toward clinical trials
The funding will push the company's preclinical drug candidates into human testing and widen its work into new therapeutic areas.
The funding will push the company's preclinical drug candidates into human testing and widen its work into new therapeutic areas.
The moves return the firm to a smaller structure centred on Silicon Valley, with the full effect still unclear to the firm itself.
The funding gives the AI assistant startup more room to scale after a fast launch and early revenue growth.
The fast uptake of Jev in large enterprises gives TypeSafe a major new signal after launching the non-text model on Sept. 15.
Core ships with local AI models and a Blackwell GPU, with the first batch due to ship in the last week of October.
Most of that agent traffic is cached prompt activity, which shifts the pressure from billing to memory capacity.